Elevated serum levels of human relaxin-2 in patients with esophageal squamous cell carcinoma

Table 2 Levels of serum human relaxin 2 in patients with esophageal squamous cell carcinoma

Category	H2 RLN (ng/mL)	P value
Normal control (n = 112)	0.34 ± 0.12	0.0261
ESCC (n = 141)	0.48 ± 0.17
Tumor status		0.1422
T1 (n = 16)	0.32 ± 0.08
T2 (n = 14)	0.53 ± 0.13
T3 (n = 75)	0.49 ± 0.16
T4 (n = 36)	0.47 ± 0.19
Lymph node involvement		0.0141
Positive (n = 90)	0.74 ± 0.15
Negative (n = 51)	0.45 ± 0.12
Distant metastasis		0.0161
Positive (n = 32)	0.90 ± 0.19
Negative (n = 109)	0.43 ± 0.14
Lymphovascular invasion		0.3422
Positive (n = 42)	0.51 ± 0.18
Negative (n = 99)	0.46 ± 0.16
Stage (TNM)		0.0022
I (n = 17)	0.42 ± 0.09
II (n = 37)	0.46 ± 0.12
III (n = 53)	0.47 ± 0.14
IV (n = 34)	0.82 ± 0.23
Cell differentiation		0.5421
Well (n = 23)	0.46 ± 0.21
Moderate (n = 90)	0.48 ± 0.13
Poor (n = 28)	0.52 ± 0.12

P value was determined by:

¹Student’s t test (two-tailed) or

²one way analysis of variance test. ESCC: Esophageal squamous cell carcinoma; H2 RLN: Human relaxin 2; TNM: Tumor-node-metastasis.